Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin

BACKGROUND: The cardiovascular (CV) benefits of sodium-glucose transport protein 2 inhibitors have been attributed, in part, to cardiac reverse remodelling. The EMPA-HEART CardioLink-6 study reported that sodium-glucose cotransporter-2 inhibition for 6 months with empagliflozin was associated with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Puar, Pankaj, Hibino, Makoto, Mazer, C. David, Yan, Andrew T., Pandey, Arjun K., Quan, Adrian, Teoh, Hwee, Hess, David A., Verma, Raj, Connelly, Kim A., Verma, Subodh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303338/
https://www.ncbi.nlm.nih.gov/pubmed/37380983
http://dx.doi.org/10.1186/s12933-023-01849-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303338/
https://www.ncbi.nlm.nih.gov/pubmed/37380983
http://dx.doi.org/10.1186/s12933-023-01849-w

Ejemplares similares